¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Positive Transcriptional Elongation Factor B"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® intermittent positive pressure breathing(IPPB) ÇÑ±Û °£ÇæÀû¾ç¾ÐÈ£Èí
¼³¸í   
  Æó¸¦ ÆØÃ¢½Ã۱â À§ÇÏ¿© ´ë±â¾Ðº¸´Ù ³ôÀº ¾Ð·ÂÀ» ÀÌ¿ëÇϴ ÀΰøÈ£Èí¹ýÀÌ´Ù. ½Å»ý¾Æ ¹«±âÆóÀÇ Ä¡·á³ª ¸¸¼º Æó¼â¼º È£Èí±â ÁúȯÀÇ ±Þ¼º ¾ÇÈ­½Ã, Áø´ÜÀ» À§ÇÑ °¡·¡ÀÇ ¹èÃâÀ» À§ÇÏ¿©, ¶Ç´Â ¾àÁ¦ÀÇ ÈíÀÔ¿¡ »ç¿ëÇϰí ÀÖ´Ù. ÇÕº´ÁõÀ¸·Î °ø±â°¡½¿ÁõÀ̳ª ½É¹ÚÃâ·®ÀÇ °¨¼Ò°¡ ¿Ã ¼ö ÀÖ´Ù.
¿µ¹® rheumatoid factor ÇÑ±Û ·ù¸¶Æ¼½º ÀÎÀÚ
¼³¸í   
  IgGÀÇ FcºÎÀ§¿¡ Àִ Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼­ ÀüÇüÀûÀΠ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) È¯ÀÚÀÇ 80%¿¡¼­ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀڴ IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁַΠIgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇϴ ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù
¿µ¹® growth factor ÇÑ±Û ¼ºÀåÀÎÀÚ
¼³¸í   
  ¼¼Æ÷ÀÇ ºÐÈ­ ¹× ¼ºÀå¿¡ °ü¿©Çϴ ´Ü¹éÁú. ¼ºÀåÀÎÀڴ Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ Å¾ÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù.
¿µ¹® risk factor ÇÑ±Û À§ÇèÀÎÀÚ
¼³¸í   
  ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼­ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î Ã¤ÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£­3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£­3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ À־ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£­3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼­ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» Çϸ鼭 ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£­3/SvÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • elongation factor
    ´ÃÀÓÀÎÀÚ, ¿¬ÀåÀÎÀÚ
  • elongation
    1. ½ÅÀå 2. ¿¬Àå 3. ´Ã¸®±â
  • automatic intermittent positive pressure
    ÀÚµ¿°£Çæ¾ç¾Ð
  • automatic intermittent positive pressure respirator
    ÀÚµ¿°£Çæ¾ç¾ÐÈ£Èí±â
  • biologic false positive reaction
    »ý¹°ÇÐÀû°ÅÁþ¾ç¼º¹ÝÀÀ
  • continuous positive airway pressure
    Áö¼Ó±âµµ¾ç¾Ð
  • continuous positive pressure breathing
    Áö¼Ó¼º¾ç¾ÐÈ£Èí(¹ý)
  • chromatin-positive
    ¿°»öÁú¾ç¼º-
  • false positive
    °ÅÁþ¾ç¼º, °¡¾ç¼º
  • false positive reaction
    °ÅÁþ¾ç¼º¹ÝÀÀ, °¡¾ç¼º¹ÝÀÀ
  • gram-positive
    ±×¶÷¾ç¼º-
  • gram-positive bacterium
    ±×¶÷¾ç¼º±Õ
  • intermittent positive pressure breathing
    °£Çæ¾ç¾ÐÈ£Èí
  • intermittent positive pressure ventilation
    °£Çæ¾ç¾Ðȯ±â(¹ý)
  • positive
    1. ¾ç¼º- 2. ±àÁ¤-
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • positive pressure breathing
    ¾ç¾ÐÈ£Èí(¹ý)
  • positive ion
    ¾çÀÌ¿Â
  • positive pressure
    ¾ç¾Ð, Á¤¾Ð
  • positive end expiratory pressure
    ³¯¼û³¡¾ç¾Ð, È£±â¸»¾ç¾Ð
  • positive sign
    È®Á¤Â¡ÈÄ
  • positive transference
    ±àÁ¤ÀüÀÌ
  • noninvasive positive-pressure ventilation
    ºñħ½À¾ç¾Ðȯ±â
  • positive predictive value
    ¾ç¼º¿¹ÃøÄ¡
  • factor
    ÀÎÀÚ, ¿äÀÎ, °è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • coagulation V factor
    Á¦5Ç÷¾×ÀÀ°íÀÎÀÚ
  • exclusion of confounding factor
    ±³¶õº¯¼ö¹èÁ¦
  • growth factor
    ¼ºÀåÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • elongation factor
    ´ÃÀÓÀÎÀÚ, ¿¬ÀåÀÎÀÚ
  • cervical elongation
    Àڱøñ¿¬Àå, ÀڱðæºÎ¿¬Àå
  • elongation
    ¿¬Àå
  • automatic intermittent positive pressure
    ÀÚµ¿°£Çæ¾ç¾ÐÈ£Èí±â
  • automatic intermittent positive pressure respirator
    ÀÚµ¿°£Çæ¾ç¾ÐÈ£Èí±â
  • positive acceleration
    ¾ç¼º°¡¼Ó
  • positive afterimage
    ¾ç¼ºÀÜ»ó
  • biologic false positive reaction
    »ý¹°ÇÐÀû°ÅÁþ¾ç¼º¹ÝÀÀ
  • continuous positive pressure breathing
    Áö¼Ó¼º¾ç¾ÐÈ£Èí(¹ý)
  • Gram-positive bacterium
    ±×¶÷¾ç¼º±Õ
  • intermittent positive pressure breathing
    °£Çæ¾ç¾ÐÈ£Èí
  • positive pressure breathing
    ¾ç¾ÐÈ£Èí(¹ý)
  • continuous positive airway pressure
    Áö¼Ó¼º±âµµ¾ç¾Ð
  • positive convergence
    ¾ç¼º´«¸ðÀ½
  • positive conversion
    ¾çÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • F factor (fertility factor)
    FÀÎÀÚ, ¼öÅÂÀÎÀÚ
  • Catalase-positive organism
    īŸ¶óÁ¦ ¾ç¼º ¼¼±Õ
  • Gram positive
    ±×¶÷¾ç¼º.
  • Gram positive bacterium
    ±×¶÷¾ç¼º±Õ.
  • Gram positive organism
    ±×¶÷¾ç¼º¼¼±Õ.
  • IPPB= intermittent positive pressure breathing
    °£ÇæÀû(ÊàúÎîÜ) ¾ç¾ÐÈ£Èí(åÕäâû¼ýå).
  • IPPB=£¾intermittent positive pressure breathing
    °£ÇæÀû ¾ç¾ÐÈ£Èí.
  • PANSS=Positive and Negative Syndrome Scale
    ¾ç¼º À½¼º ÁõÈıº ôµµ
  • PEEP(positive end-expiratory pressure)
    È£±â¸» ¾ç¾ÐÈ£Èí
  • Rh positive
    Rh ¾ç¼º
  • SAPS, Scale for the Assessment of Positive Symptoms
    ¾ç¼ºÁõ»óÆò°¡Ã´µµ
  • gram positive organism
    ±×·¥¾ç¼º¼¼±Õ.
  • hallucination, positive
    ¾ç¼ºÈ¯°¢(åÕàõü³ÊÆ)
  • high frequency positive pressure ventilation =HFPPV
    °íºóµµ¾ç¾Ðȯ±â.
  • positive acceleration
    ¾ç°¡¼Óµµ(Çö»ó)(åÕÊ¥áÜöôúÞßÚ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • elongation factor
    ¿¬ÀåÀÎÀÚ(¡­ì×í­).
  • elongation factor
    ½ÅÀåÀÎÀÚ
  • cervical elongation<³ª> elongatio colli
    Àڱð濬Àå(í­ÏàÌòæÅíþ).
  • elongatio colli =cervical elongation<³ª>
    Àڱð濬Àå(í­Ïà æÅíþ).
  • elongation
    ´Ã±â
  • elongation of aorta
    ´ëµ¿¸Æ´Ã±â, ´ëµ¿¸Æ(ÓÞÔÑØæ)¿¬Àå.
  • elongation of tooth
    Ä¡¾ÆÁ¤Ãâ(öÍä³ïØõó).
  • elongation percentage
    ½ÅÀå·ü(ãßíþëÒ).
  • load elongation diagram
    ÇÏÁß½ÅÀå·ü»óŵµ(̡̰ËàËöËôË×̬ËÀ).
  • col factor(»ýÈ­) cÀÌ ÀÎÀÚ colicin factor
    Äݸ®½ÅÀÎÀÚ.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • time, dose and fractionation factor, TDF factor
    ½Ã°£¼±·®ºÐÇÒÀÎÀÚ
  • automatic intermittent positive pressure
    ÀÚµ¿°£ÇæÀû ¾ç¾ÐÈ£Èí±â.
  • automatic intermittent positive pressure respir ator
    ÀÚµ¿°£ÇæÀû ¾ç¾ÐÈ£Èí±â.
  • automatic intermittent positive pressure respirator
    ÀÚµ¿°£ÇæÀû ¾ç¾ÐÈ£Èí±â.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Elongation
    ´Ã±â
    [¿¾ ¿ë¾î] ½ÅÀå
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Duffy factor
    ´õÇÇÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • elongation factor
    ¿¬ÀåÀÎÀÚ (æÅíþì×í­)
  • transcriptional control
    Àü»ç Á¦¾î(ï®ÞÐð¤åÙ)
  • transcriptional enhancxer
    Àü»ç(ï®ÞÐ) ¿£Çî¼­
  • chain elongation
    »ç½½¿¬Àå(æÅíþ)
  • elongation
    ¿¬Àå(æÅíþ)
  • elongation cycle
    ¿¬ÀåÁÖ±â (æÅíþñÎÑ¢)
  • positive catalysis
    "°¡Ã˸Å(ʦõºØÚ), ¾ç¼ºÃ˸Å(åÕàõõºØÚ)"
  • positive control
    "°¡Á¶Àý(ʦðàï½), ¾ç¼ºÁ¶Àý(åÕàõðàï½)"
  • positive cooperativity
    "°¡Çùµ¿¼º(ʦúðÔÒàõ), ¾ç¼ºÇùµ¿¼º(åÕàõúðÔÒàõ)"
  • positive effector
    "°¡È¿°úü(ʦüùÍýô÷), ¾ç¼ºÈ¿°úü(åÕàõüùÍýô÷)"
  • positive electron
    ¾çÀüÀÚ(åÕï³í­)
  • positive feedback
    "°¡(ʦ)µÇ¸ÔÀÓ, ¾ç¼º(åÕàõ)µÇ¸ÔÀÓ"
  • positive gene control
    "°¡À¯ÀüÀÚÁ¶Àý(ʦë¶îîí­ðàï½), ¾ç¼ºÀ¯ÀüÀÚÁ¶Àý, (åÕàõë¶îîí­ðàï½)"
  • positive hydration
    °¡¼öÈ­(Ê¥â©ûù)
  • positive polarity
    ¾ç±Ø¼º(åÕпàõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • elongation
    ¿¬Àå, ÆØÃ¢
  • false positive
    °¡¾ç¼º
  • intermittent positive pressure ventilation
    °£ÇæÀû¾ç¾Ðȯ±â¹ý
  • positive
    ¾ç(¼º)ÀÇ, ¹Ù¸¥
  • positive balance
    ¾ç¼º¼öÁö
  • positive contrast medium
    ¾ç¼ºÁ¶¿µÁ¦
  • positive predictive value [=PPV]
    ¾ç¼º¿¹ÃøÄ¡
  • positive pressure
    ¾ç¾Ð, Á¤¾Ð
  • attenuation factor
    °¨¾à¿ä¼Ò, °¨¼è¿äÀÎ
  • conversion factor
    º¯È¯ÀÎÀÚ
  • factor
    ÀÎÀÚ
  • predisposing factor
    ¼ÒÀÎ, Áúº´¼ÒÁú
  • Q factor
    Å¥ÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½º¾çÀÎÀÚ
  • risk factor
    À§Çè¿äÀÎ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
CF calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ...
TEF thermic effect of food; thyrotroph embryonic factor; tracheoesophageal fistula; transcriptional enha...
PF pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
P-TEFb positive transcription elongation factor b
TEF-1 Transcriptional Enhancer Factor-1
PTGS Post-transcriptional gene silencing
RT-PCR Reverse transcriptional-polymerase chain reaction
tsp Transcriptional start point
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • elongation
    ½ÅÀå, Á¤Ãâ, ¿¬Àå, ÆØÃ¢, ¿¬½ÅÀ²
    1. ¹°Ã¼ÀÇ Å©±â³ª ¼¼·Â µûÀ§°¡ ´Ã¾î³ª°í ÆîÃÄÁö´Â °Í. 2. ¿ø·¡ Àç·á¿¡¼­ ±× Àç·á°¡ ´Ã¾î³ª´Â ºñÀ².
  • elongation percentage
    ½ÅÀå·ü
  • load-elongation diagram
    ÇÏÁß ½Åµµ
    Àç·áÀÇ ÀÎÀå ½ÃÇè¿¡¼­ ÇÏÁßÀ» 0¿¡¼­ºÎÅÍ Á¡Â÷ Áõ°¡½ÃÄÑ °¥ ¶§ »ý±â´Â ½ÃÇèÆíÀÇ ´Ã¾î³²À» ȾÁÂÇ¥·Î ÃëÇϰí, ±×°Í¿¡ ¸Â¸Ô´Â ÇÏÁßÀÇ Å©±â¸¦ Á¾ÁÂÇ¥¿¡ ÃëÇÏ¿© ±×¸° ±×¸²À» ÇÏÁß ½Åµµ¶ó°í ÇÑ´Ù. ÀÎÀå ½ÃÇè±âÀÇ ´ëºÎºÐÀº ±× ÇÏÁß ½Åµµ¸¦ ÀÚµ¿ÀûÀ¸·Î ±×¸± ¼ö ÀÖ´Â ÀÚµ¿ ±â·Ï ÀåÄ¡¸¦ °®Ãß°í ÀÖ´Ù.
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • automatic intermittent positive pressure respirator
    ÀÚµ¿ °£ÇæÀû ¾ç¾Ð È£Èí±â
  • biologic false positive reaction
    »ý¹°ÇÐÀû °¡¾ç¼º ¹ÝÀÀ
  • chromatin-positive
    ¿°»öÁú ¾ç¼ºÀÇ
    »ó¿°»öü ¼¼Æ÷ ÇÙ¿¡ ¼º ¿°»öÁúÀ» °®°í ÀÖ´Â. Á¤»ó ¾ÏÄÆÀÇ Æ¯Â¡ÀÌ´Ù.
  • continuous positive airway pressure
    Áö¼Ó¼º ±âµµ ¾ç¾Ð
  • false positive reaction
    °¡¾ç¼º ¹ÝÀÀ
  • false-positive diagnosis
    À§ ¾ç¼º Áø´Ü
  • intermittent positive pressure breathing
    °£ÇæÀû Á¤¾Ð È£Èí¹ý
    ¼øÈ¯ÆÇÀ¸·ÎºÎÅÍÀÇ ÀÏÁ¤ ¾Ð·ÂÇÏ¿¡¼­ ÈíÀÔÇÏ´Â µ¿¾È¿¡ Æó°¡ ÀÚµ¿ÀûÀ¸·Î ÆØÃ¢ÇÏ´Â °Í.
  • positive
    ¾ç¼º, ¾çÀÇ, ¾ç¼ºÀÇ, ¹Ù¸¥
  • positive after potential
    ¾ç¼º ÈÄÀüÀ§
  • positive airway pressure
    ±âµµ ¾ç¾Ð
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
peptide elongation factor tu A protein found in bacteria and eukaryotic cells which delivers aminoacyl-trna's to the a site of the ribosome. The aminoacyl-trna is first bound to a complex of elongation factor tu containing a molecule of bound GTP. The resulting complex is then bound to the 70s initiation complex. Simultaneously the GTP is hydrolyzed and a tu-GDP complex is released from the 70s ribosome. The tu-GTP complex is regenerated from the tu-GDP complex by the ts elongation factor and GTP.
(12 Dec 1998)
elongation factor <biochemistry> Peptidyltransferase components of ribosomes that catalyse formation of the acyl bond between the incoming amino acid residue and the peptide chain.
There are three classes of elongation factor: EF1_ (EF Tu in prokaryotes) binds GTP and aminoacyl tRNA, delivering it to the A site of ribosomes. EF 1_ (EF Ts) helps in regeneration of GTP EF 1_. EF 2 (EF G) binds GTP and peptidyl tRNA and translocates it from the A site to the P site. Diptheria toxin inhibits protein synthesis in eukaryotes by adding an ADP ribosyl group to a modified histidine residue (dipthamide) in elongation factor II.
(18 Nov 1997)
RNA processing, post-transcriptional Post-transcriptional biological modification of messenger, transfer, or ribosomal rnas or their precursors. It includes cleavage, methylation, thiolation, isopentenylation, pseudouridine formation, conformational changes, and association with ribosomal protein.
(12 Dec 1998)
post-transcriptional processing The enzymatic processing of the primary RNA transcript, which producesmessenger RNA and transfer RNA.
(09 Oct 1997)
transcriptional control <molecular biology> Control of gene expression by controlling the number of RNA transcripts of a region of DNA. A major regulatory mechanism for differential control of protein synthesis in both pro and eukaryotic cells.
(18 Nov 1997)
transcriptional silencing <molecular biology> Mechanism of transcriptional control where DNA is bundled into heterochromatin in order to make it permanently inaccessible for future transcription.
Effectively, this allows for memory in the determination of cell fate in developing organisms. In Drosophila, homeotic genes are silenced by members of the Polycomb group of genes.
(17 Mar 1998)
peptide chain elongation The process whereby an amino acid is joined through a substituted amide linkage to a chain of peptides.
(12 Dec 1998)
peptide elongation factors Protein factors uniquely required during the elongation phase of protein synthesis.
(12 Dec 1998)
sign of elongation <microscopy> Referring to the elongation of a substance in relation to refractive indices. If it is elongated in the direction of the high refractive index, it is said to have a positive sign of elongation. If it is elongated in the direction of the low refractive index, it has a negative sign of elongation, not to be confused with the sign of double refraction (i.e., optic sign).
(05 Aug 1998)
elongation <radiobiology> Parameter indicating the degree to which the cross-section of a toroidal plasma is non-circular. Kappa=b/a, where b and a are the vertical and horizontal minor radii. As kappa is increased, the confinement in relation to the total current improves, but the plasma also becomes more and more unstable to vertical displacements. A circular plasma has kappa of 1, a common value for elongated plasmas is 1.7, and the absolute limit is probably around 2.
(09 Oct 1997)
CD4-positive T-lymphocytes A critical subpopulation of regulatory T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the t4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes, which includes both the helper-inducer (T-lymphocytes, helper-inducer) and suppressor-inducer (T-lymphocytes, suppressor-inducer) T-cells.
(12 Dec 1998)
CD8-positive T-lymphocytes A critical subpopulation of regulatory T-lymphocytes involved in MHC class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-lymphocytes, cytotoxic) and suppressor T-lymphocytes (T-lymphocytes, suppressor-effector).
(12 Dec 1998)
gram-positive <microbiology> Bacteria that retain the stain or that are resistant to decolourisation by alcohol during Gram's method of staining.
This is a primary characteristic of bacteria whose cell wall is composed of a thick layer of peptidologlycan containing teichoic and lipoteichoic acid complexed to the peptidoglycan.
See: gram-negative
(06 Oct 1997)
gram-positive asporogenous rods <microbiology> A gram-positive, non-spore-forming group of bacteria comprising organisms that have morphological and physiological characteristics in common.
(12 Dec 1998)
gram-positive asporogenous rods, irregular <microbiology> A group of irregular rod-shaped bacteria that stain gram-positive and do not produce endospores.
(12 Dec 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Positive Transcriptional Elongation Factor B - »õâ A transcriptional elongation factor complex that is comprised of a heterodimer of CYCLIN-DEPENDENT KINASE 9 and one of several CYCLINS including cyclin T1, T2 and K. It functions by phosphorylating the carboxy-terminal domain (CTD) of RNA POLYMERASE II, which results in more processive transcription complexes.
    Synonyms : P-TEFb, Positive Transcription Elongation Factor B, tat-Associated Kinase, tat Associated Kinase
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • elongation
    ¿¬Àå;½ÅÀå
  • factor
    ¿ä¼Ò,¿äÀÎ
  • F factor
    FÀÎÀÚ;¿°¼ºÀÎÀÚ
  • R factor
    R ÀÎÀÚ(¼¼±ÕÀÇ ¾àÁ¦ ³»¼º ÀÎÀÚ)
  • Rh factor
    ¸®¼­½º ÀÎÀÚ(ÀûÇ÷±¸ ¼Ó¿¡ ÀÖ´Â ÀÀÇ÷¼Ò)
  • Rhesus factor(antigen)
    =RH FACTOR
  • coal-factor
    ¼®Åº Áß°³ »óÀÎ(µµ¸Å »óÀÎ)
  • common factor
    =COMMON DIVISOR
  • conversion factor
    (¹®ÀÇ.ÀÚ·áû±¸¿¡¼­ ½ÇÁ¦ »óǰ±¸¸ÅÀÎÀ¸·ÎÀÇ)ÀüȯÀ²
  • factor
    ¿ä¼Ò;¿äÀÎ;¿øÀÎ;Àμö;ÀÎÀÚ;°è¼ö;À²;´ë¸®»ó;µµ¸Å»ó;Á߸ÅÀÎ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • factor cost
    ¿äÀÎ(¿ä¼­)ºñ¿ë
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á